Loading...
When patients with advanced prostate cancer develop progressive disease following androgen-deprivation therapy (i.e., castration-resistant disease), they often receive second-line hormonal therapy (typically consisting of ketoconazole or first-generation antiandrogens) prior to chemotherapy. However, these agents have limited utility in this setting. In addition, when first-generation antiandrogens are discontinued, patients can develop “withdrawal responses,” perhaps as a result of low binding affinities and partial agonist activities of these agents.
MDV3100 is a novel oral androgen-receptor antagonist that has pure antagonist activity with greater binding affinity than the available antiandrogens. Investigators in the U.S. conducted a pha…